FDA Approval of Dupixent for COPD by September 27, 2024? | Binary | | | 7 months ago | |
Will Dupixent sales grow in Q4 2024? | Binary | | | 7 months ago | |
Dupixent's Ranking Among Top-Selling Drugs Worldwide in 2024 | Categorical | | | 7 months ago | |
Sanofi Stock Price Change Within One Week After FDA Decision on Dupixent | Categorical | | | 7 months ago | |
Market Share of Dupixent in COPD Treatments in Europe by end of 2024 | Categorical | | | 7 months ago | |
Will Dupixent receive additional approvals for new indications by end of 2024? | Binary | | | 7 months ago | |
FDA approval for Emblaveo by end of 2024? | Binary | | | 8 months ago | |
Next approved treatment indication for Emblaveo | Categorical | | | 8 months ago | |
Emblaveo sales exceed $500 million by end of 2024? | Binary | | | 8 months ago | |
Impact on Pfizer's antibiotics market share by end of 2025 | Categorical | | | 8 months ago | |
Will EMA approve semaglutide for obstructive sleep apnea by end of 2025? | Binary | | | 9 days ago | |
Will FDA approve semaglutide for Alzheimer's treatment by end of 2025? | Binary | | | 9 days ago | |
Most prescribed diabetes drug in Europe by end of 2025? | Categorical | | | 9 days ago | |
Will the European Commission approve Leqembi for early Alzheimer's by March 31, 2025? | Binary | | | 1 month ago | |
Will Vutrisiran achieve multibillion-dollar sales by end of 2026? | Binary | | | 2 months ago | |
Will Vutrisiran be approved by the European Medicines Agency by October 31, 2025? | Binary | | | 2 months ago | |
Will Eisai and Biogen reapply for Leqembi approval in the EU by December 31, 2024? | Binary | | | 5 months ago | |
Largest market for Emblaveo by end of 2025 | Categorical | | | 8 months ago | |
Will WHO include semaglutide in essential medicines list by end of 2025? | Binary | | | 9 days ago | |
What will be the EC's decision on Leqembi by March 31, 2025? | Categorical | | | 1 month ago | |
What will be Novo Nordisk's Wegovy sales figures for Q4 2024? | Categorical | | | 3 months ago | |
Will Novo Nordisk's stock price increase by more than 10% by October 31, 2024? | Binary | | | 3 months ago | |
Will Biogen's stock price recover to its pre-rejection level by December 31, 2024? | Binary | | | 5 months ago | |
What will be the total US sales of Leqembi by December 31, 2024? | Categorical | | | 5 months ago | |
Pfizer partnership for Emblaveo in Asia by mid-2025? | Binary | | | 8 months ago | |
Which new indication will FDA approve semaglutide for by end of 2025? | Categorical | | | 9 days ago | |
Which condition will semaglutide most significantly impact in reducing cardiovascular events by end of 2025? | Categorical | | | 9 days ago | |
Which condition will semaglutide be adopted as a standard treatment for by end of 2025? | Categorical | | | 9 days ago | |
Outcome of vision loss study related to Ozempic by end of 2025? | Categorical | | | 9 days ago | |
Primary reason for Ozempic prescription increase in Europe post-EMA update by June 2025? | Categorical | | | 9 days ago | |
Novo Nordisk issues safety update or recall for Ozempic over vision loss by end of 2025? | Binary | | | 9 days ago | |
Mounjaro surpasses Ozempic in European diabetes treatment market share by end of 2025? | Binary | | | 9 days ago | |
Increase in Ozempic prescriptions in Europe post-EMA label update by June 2025? | Binary | | | 9 days ago | |
Will seladelpar be launched in the EU market for PBC by June 30, 2025? | Binary | | | 10 days ago | |
Number of EU countries adopting seladelpar in health systems by December 31, 2025 | Categorical | | | 10 days ago | |
Will the European Commission approve seladelpar for PBC by March 31, 2025? | Binary | | | 10 days ago | |
Will seladelpar achieve over 50% market share in the EU PBC treatment market by December 31, 2025? | Binary | | | 10 days ago | |
Seladelpar's approval status by EMA and FDA by December 31, 2025 | Categorical | | | 10 days ago | |
Seladelpar's impact on ALP levels in follow-up studies by December 31, 2025 | Categorical | | | 10 days ago | |
Will Biogen's stock rise over 10% within 30 days of EC's Leqembi decision? | Binary | | | 1 month ago | |
Will Leqembi be approved by another major regulatory body by end of 2025? | Binary | | | 1 month ago | |
How will Biogen's stock change one week after EC's Leqembi decision? | Categorical | | | 1 month ago | |
What will be Leqembi's market penetration in Europe within a year of approval? | Categorical | | | 1 month ago | |
Will diagnosis rates for ATTR amyloidosis with cardiomyopathy increase by end of 2025? | Binary | | | 2 months ago | |
What will be the outcome of Vutrisiran's regulatory application to the European Medicines Agency by October 31, 2025? | Categorical | | | 2 months ago | |
What will be Alnylam Pharmaceuticals' rank among biotech companies by market cap by end of 2025? | Categorical | | | 2 months ago | |
Who will be the leading competitor to Vutrisiran in the ATTR amyloidosis market by end of 2025? | Categorical | | | 2 months ago | |
How many new prescriptions for Wegovy will be issued in Europe by March 31, 2025? | Categorical | | | 3 months ago | |
Will Wegovy receive FDA approval for heart failure label update by March 31, 2025? | Binary | | | 3 months ago | |
What will be the market share of GLP-1 medications in Europe by end of Q2 2025? | Categorical | | | 3 months ago | |
Will EMA finalize the label update for Wegovy to include heart failure benefits by end of 2024? | Binary | | | 3 months ago | |
What will be the next major regulatory decision on Leqembi by December 31, 2024? | Categorical | | | 5 months ago | |
Will Leqembi be approved in another major market outside the US and EU by December 31, 2024? | Binary | | | 5 months ago | |
How will Biogen's stock price compare to its competitors by December 31, 2024? | Categorical | | | 5 months ago | |